Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
[Appraisal of the formation of afterimages by means of a new computer application in patients with demyelinating optic neuropathies].
Central pontine myelinolysis caused by hypernatremia.
Meeting the mental health needs of people with multiple sclerosis: a qualitative study of patients and professionals.
2'-5' oligoadenylate synthetase-like 1 (OASL1) deficiency suppresses central nervous system damage in a murine MOG-induced multiple sclerosis model.
[Improving the sexual quality of life of people with multiple sclerosis].
YAP and TAZ control peripheral myelination and the expression of laminin receptors in Schwann cells.
Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.
Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists.
Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
A human anti-polysialic acid antibody as a potential treatment to improve function in multiple sclerosis patients.
Fatigue and Fatigability in Persons with Multiple Sclerosis.
The hypothetical roles of arsenic in multiple sclerosis by induction of inflammation and aggregation of tau protein: A commentary.
Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments.
Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk.
Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
Postural tremor and chronic inflammatory demyelinating polyneuropathy.
Iron uptake and transport across physiological barriers.
Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study.
Neuropilin-1 modulates interferon-γ-stimulated signaling in brain microvascular endothelial cells.
Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.
Stress Urinary Incontinence in Women With Multiple Sclerosis.
Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis.
Pros and cons of medical cannabis use by people with chronic brain disorders.
Chaperome screening leads to identification of Grp94/Gp96 and FKBP4/52 as modulators of the α-synuclein-elicited immune response.
Pages
« first
‹ previous
…
829
830
831
832
833
834
835
836
837
…
next ›
last »